Loading
A phase 1/2 trial of Fludarabine, Cyclophosphamide in pancreatic ductal adenocarcinoma, run by Beijing Biotech, now recruiting.
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma is a phase 1/2 interventional study registered as NCT07627711 by Beijing Biotech, with 42 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-04-14. Interventions recorded: EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy). Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, Metastatic Disease. No results are recorded here; the registry entry is the source.
Shares Fludarabine, Cyclophosphamide, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Fludarabine, Cyclophosphamide, Metastatic pancreatic ductal adenocarcinoma.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide, Pancreatic ductal adenocarcinoma.
Shares Fludarabine, Cyclophosphamide.